The ARTILLERY project was proudly represented at the European Breast Cancer Conference EBCC-15, one of the most important international conferences in the field of breast cancer, held from 25–27 March in Barcelona.
During the congress, Sharminii Jaya Prakason and Sofie Gernaat from UMC Utrecht presented the ARTILLERY Cardi Trial (CarDI) study through a scientific poster, highlighting an important step towards integrating long-term risk assessment into breast cancer care.
The CarDI study is part of the ARTILLERY project and focuses on identifying cardiovascular disease (CVD) risk in breast cancer patients undergoing radiotherapy. More broadly, ARTILLERY aims to improve early detection of increased risk for four chronic conditions in breast cancer survivors: cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), osteoporosis, and weight gain.
By using routinely acquired planning CT scans, the project explores how AI-supported risk prediction can contribute to more personalised care and follow-up. A key aspect of the CarDI study is also understanding the decision impact—how this information may influence both clinical decision-making and patients’ awareness of long-term health risks.
During the poster presentation, other ARTILLERY consortium partners also stopped by the poster: Prof. dr. Nadia Harbeck from Ludwig-Maximilians-Universität München, and dr. Tanja Španić and Darja Molan from Europa Donna Slovenija. All three were at EBCC-15 as invited speakers in their respective fields, showing the strong clinical expertise and patient advocacy within the ARTILLERY project.
We are very pleased that the ARTILLERY project was visible at EBCC-15 and proud that our work continues to be shared at major international conferences.
